Skip to content
Landing Page Graphic-01

Custom Ophthalmic Drug Delivery Devices

From early development through commercialization, we help bring ophthalmic drug-delivery devices 
to market, including implant injectors, liquid injectors, eye droppers, and topical applicators.

 

Upcoming tradeshows and conferences 

PDA

Oct 21 - Oct 22, 2025
Vienna, Austria
Hall X2, #150

PODD

Oct 27 -Oct 29, 2025
Boston, MA, USA
#26

CPHI

Oct 28 - Oct 30, 2025
Frankfurt, Germany
Hall 8, #0J92

Don’t miss our presentations at PODD and CPHI!

  • PODD
    • Monday, October 27, 2025 – 05:30 PM - 05:45 PM
      A Novel Approach to Modelling Injector Performance and Break-Loose Extrusion Force Data
      Presenter: Tom Oakley, Springboard, co-presenting with Deep Bhattacharya, Pfizer
  • CPHI
    • Wednesday, October 29, 2025 – 11:35 AM - 12:05 PM
      Rethinking Injector Mechanics – A New Approach to BLEF-Based Modelling
      Speakers: Tom Oakley, Springboard, co-presenting with Jay Sayed, Pfizer
    • Wednesday, October 29, 2025 – 12:05 PM - 12:20 PM
      Modelling to Market – Enabling Smarter, Faster Injector Development
      Speaker: Alex Vasiev, Springboard

Meet our experts at the conferences

Feel free to reach out to our sales representatives to arrange a meeting in advance.
Click on the images to send an email.

Christian Classen-1

Christian Classen
Chief Sales Officer, CSO
PDA, CPHI

Tom Oakley

Tom Oakley
VP Strategic Design & Development Partnerships (Europe)
PODD, CPHI

01-geoff-jones2

Geoff Jones
Vice President Sales, CDMO
PDA, CPHI

Ed Butler

Ed Butler
Business Development Manager
PDA, PODD

03-chuck-crandley

Chuck Crandley
Business Development Manager
PODD

Sven Dasbach

Sven Dasbach
Business Development Manager
CPHI

Paula Dominguez

Paula Domínguez
Business Development Manager
CPHI

Joe Masci

Joe Masci
Business Development Manager
PODD

Cameron Palagruto

Cameron Palagruto
Business Development Manager
PODD

Alex Vasiev

Alex Vasiev
Business Development Manager
CPHI

  

Experts in Designing and Manufacturing Solid and Liquid Dose Delivery Devices

Our team brings experience in designing devices across a range of active ingredients, including hydrogels, sustained-release solids, and small-molecule drug liquids. 

a generic device used to inject drug in the s-1
Concept Development 1

Human Centered Design

Proven expertise in injection device design that balances patient outcomes with manufacturability.

Device Design and Engineering

Device Development

Holistic combination-product support from an expert device partner, ensuring device and program success.

csm_Sanner_Werkbank-2_ad98ab71ec

Scalable Manufacturing

In-house clinical-grade component and final assembly manufacturing to support increasing production volumes. 

Your expert partner for developing and manufacturing 
custom ophthalmic drug delivery devices

Screenshot 2026-02-26 093257

Sanner’s Robust Approach to Ocular Injection Devices

Our specialized expertise in ophthalmic injection device development supports ocular therapeutics programs from pre-clinical stages through commercialization.

With proven know-how in bringing ophthalmic injectors to market, we serve as a reliable device partner throughout your product’s journey to market success. We collaborate closely with your existing pharmaceutical manufacturing team to ensure seamless integration of drug and device as your clinical program progresses.

More Insights on Ophthalmic Drug Delivery

Worldwide production capacity and device development services

Sanner operates a global manufacturing network with a total production space of 28,500 sqm, including 11,000 sqm of cleanroom space (Class 7/8). Our Design Centers of Excellence, Springboard and Gilero, are strategically located in the UK and across the US. Our manufacturing facilities are based in the US, Asia and Europe.

Sanner locations

 
How we can help you

  • Capacity for small-batch prototypes and scaling to full production. Our facilities are equipped to handle a wide range of production needs:
    • High precision fully electric thermoplastic injection molding capable of handling small shot weights (around 0.1g) up to 64-cavity molds (max. 350T), including 2K molding with thermoplastic elastomers (TPE). 
    • Manual assembly up to fully automated assembly processes, incorporating mechatronic components for enhanced efficiency and precision.
    • End of line packaging for sub-assemblies or finished goods
    • Sterilization through trusted external partners, utilizing validated processes to ensure compliance with industry standards.
  • Our experience in successfully transferring innovations to production across the EU, US, and China speaks to our ability to bring cutting-edge technologies to global markets. All phases of device development can be supported from our Design and Development Centers of Excellence in both the US and EU. 
  • Our design transfer processes enable the smoother path to market. We offer end-to-end thinking from development to manufacturing all under one roof to de-risk your project and for a better time to market.
  • Our reliability and collaborative working attitude support you in any stage of your project.

 

Quality control processes and compliance with ISO 13485

Sanner Group facilities are ISO 13485 certified for Design & Development and Manufacturing respectively. Over 250 ISO, AAMI/ANSI standards are used routinely. Our streamlined quality system satisfies the FDA requirements for both the device quality system regulations and the part 210/211 cGMP regulations.

 

Gene Therapy and ophthalmic drug delivery

WHITEPAPER

Gene Therapy in Ophthalmology

amanda-dalbjorn-UbJMy92p8wk-unsplash-2-1024x683

WHITEPAPER

Measuring Intraocular Pressure Correctly

Ocular-Injector-scaled-1

CASE STUDY

Designing an Ocular Implant Injector

Talk to an expert
Talk to us today about your next device development project.